Clinical trial
Study Evaluating rhMBP-2/CPM in Open Wedge Osteotomies
NCT00243295 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00243295 |
|---|---|
| Title | Study Evaluating rhMBP-2/CPM in Open Wedge Osteotomies |
| Official title | A Pilot Study to Validate the Feasibility of Injecting and Monitoring Recombinant Human Bone Morphogenetic Protein-2/Calcium Phosphate Matrix (rhBMP-2/CPM) in Subjects With Open Wedge Osteotomies |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Osteoarthritis |
| Intervention type | Drug |
| Interventions | rhBMP-2/CPM |
| Enrollment | 6 |
| Start date | Nov 1, 2003 |
| Completion | Mar 1, 2005 |
| First posted | Oct 21, 2005 |
| Last update posted | Oct 6, 2006 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: